Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO).
Methods: Prospective, open-label, nonrandomized clinical trial of patients with AMD, DME, or RVO who were antivascular endothelial growth factor (VEGF) naïve or had not received anti-VEGF for ≥4 months. Patients received 3 monthly intravitreal injections of aflibercept 2.0 mg, bevacizumab 1.25 mg, or ranibizumab (0.5 mg for AMD/RVO, 0.3 mg for DME). The main outcome measures were serum PKs and plasma free-VEGF concentrations after the first and third injections.
Results: A total of 151 patients were included. In AMD/DME/RVO, systemic exposure to each drug was highest with bevacizumab, then aflibercept, and lowest with ranibizumab. Ranibizumab cleared from the bloodstream more quickly than bevacizumab or aflibercept. Aflibercept treatment resulted in the greatest reductions in plasma free-VEGF relative to baseline levels, whereas ranibizumab treatment resulted in the smallest decreases in plasma free-VEGF.
Conclusion: The three anti-VEGF treatments examined in this analysis demonstrated notable differences in systemic PKs. Generally, the reduction in plasma free-VEGF levels correlated with elevated levels of circulating anti-VEGF agents, with the reduction in free-VEGF levels greatest with aflibercept and least with ranibizumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642319 | PMC |
| http://dx.doi.org/10.1097/IAE.0000000000001493 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravitreal anti-VEGF therapy and risk of limb complications in individuals with diabetic eye disease.
Diabetes Res Clin Pract
September 2025
Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:
Aims: To evaluate the association between intravitreal anti-VEGF therapy and lower extremity complications in diabetic eye disease (DED), and compare risks among ranibizumab, aflibercept, and bevacizumab.
Methods: This retrospective cohort study used a U.S.
Anti-Vascular Endothelial Growth Factor Therapy for Stages 3 and 4 Proliferative Sickle Cell Retinopathy Results in Improved Anatomic and Visual Outcomes.
Retina
August 2025
Department of Ophthalmology, University of Illinois at Chicago and Illinois Eye and Ear Infirmary, Chicago, IL.
Purpose: To investigate the potential utility of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for stages 3 and 4 proliferative sickle cell retinopathy (PSR).
Methods: Retrospective review of anatomic and visual acuity outcomes after intravitreal anti-VEGF therapy for stages 3 and 4 PSR eyes.
Results: There were 45 PSR eyes (17 stage 3 and 28 stage 4) treated with anti-VEGF agents (bevacizumab (37 eyes), aflibercept (6 eyes), ranibizumab (3 eyes), one eye received 2 both bevacizumab and aflibercept).
Effect of Faricimab on Visual Acuity and Retinal Structure in Neovascular Age-Related Macular Degeneration Previously Treated With Anti-VEGF Therapy.
J Vitreoretin Dis
August 2025
Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA.
To evaluate the effects of switching from traditional antivascular endothelial growth factor (anti-VEGF) therapies to faricimab, a biclonal antibody that targets both VEGF and angiopoietin-2, on eyes with neovascular age-related macular degeneration (nAMD). This study retrospectively reviewed patients with nAMD who were previously treated with bevacizumab, ranibizumab, or aflibercept and then switched to faricimab. We compared injection frequency and visual acuity (VA) during the time period before faricimab initiation (1 year prior) and after initiation (6-12 months after).
View Article and Find Full Text PDFEffects of Socioeconomic Factors on Visual Outcome and Management of Wet Age-Related Macular Degeneration Patients.
Retina
August 2025
University of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Miami, FL, USA.
Purpose: To analyze the relationship between socioeconomic status (SES) and neovascular age-related macular degeneration (nAMD) outcomes and management.
Methods: Retrospective analysis of 1449 patients diagnosed with nAMD, treated with anti-VEGF between January 2016-January 2024.
Results: Lower income was associated with poorer baseline (p < .
Comparative efficacy of aflibercept, bevacizumab, and ranibizumab on hard exudate resolution in diabetic macular edema.
Can J Ophthalmol
August 2025
Doheny Eye Institute, Pasadena, CA, United States; Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States. Electronic address:
Objective: To compare the efficacy of aflibercept, bevacizumab, and ranibizumab for resolution of diabetic macular edema-associated hard exudates (HEs).
Design: Post hoc analysis of the Diabetic Retinopathy Clinical Research Network Protocol T trial.
Participants: Two hundred and forty-eight subjects with 84 eyes were treated with aflibercept, 71 eyes were treated with bevacizumab, and 93 eyes were treated with ranibizumab.